JP2024525512A5 - - Google Patents

Info

Publication number
JP2024525512A5
JP2024525512A5 JP2023581003A JP2023581003A JP2024525512A5 JP 2024525512 A5 JP2024525512 A5 JP 2024525512A5 JP 2023581003 A JP2023581003 A JP 2023581003A JP 2023581003 A JP2023581003 A JP 2023581003A JP 2024525512 A5 JP2024525512 A5 JP 2024525512A5
Authority
JP
Japan
Prior art keywords
nucleic acid
composition
optionally
condition
chemically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023581003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525512A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/035866 external-priority patent/WO2023278799A1/en
Publication of JP2024525512A publication Critical patent/JP2024525512A/ja
Publication of JP2024525512A5 publication Critical patent/JP2024525512A5/ja
Pending legal-status Critical Current

Links

JP2023581003A 2021-07-01 2022-06-30 治療用核酸及びその使用方法 Pending JP2024525512A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202970P 2021-07-01 2021-07-01
US63/202,970 2021-07-01
PCT/US2022/035866 WO2023278799A1 (en) 2021-07-01 2022-06-30 Therapeutic nucleic acids and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024525512A JP2024525512A (ja) 2024-07-12
JP2024525512A5 true JP2024525512A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84690648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023581003A Pending JP2024525512A (ja) 2021-07-01 2022-06-30 治療用核酸及びその使用方法
JP2023581043A Pending JP2024527340A (ja) 2021-07-01 2022-06-30 核酸の経口送達用の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023581043A Pending JP2024527340A (ja) 2021-07-01 2022-06-30 核酸の経口送達用の製剤

Country Status (8)

Country Link
US (2) US20240285668A1 (cg-RX-API-DMAC7.html)
EP (2) EP4363434A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024525512A (cg-RX-API-DMAC7.html)
KR (2) KR20240028486A (cg-RX-API-DMAC7.html)
CN (2) CN117897162A (cg-RX-API-DMAC7.html)
AU (2) AU2022303330A1 (cg-RX-API-DMAC7.html)
CA (2) CA3223495A1 (cg-RX-API-DMAC7.html)
WO (2) WO2023278802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
KR20250078993A (ko) * 2022-09-30 2025-06-04 세다르스-신나이 메디칼 센터 치료용 핵산 및 그의 사용 방법
KR20260074974A (ko) * 2023-09-15 2026-05-27 세다르스-신나이 메디칼 센터 유전독성 스트레스를 약화시키고 심장 보호 효과를 발휘하는 trex-1 증강제
WO2026035943A1 (en) 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids
WO2026035744A1 (en) 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Combination therapies for metabolic disease
KR20260065643A (ko) * 2024-10-31 2026-05-11 성균관대학교산학협력단 CU-rich RNA를 포함하는 근위축증 또는 근육 손상의 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
DK2182969T3 (en) * 2007-07-31 2017-02-27 Univ Texas Micro-RNA family that modulates fibrosis and its applications
CN102639700A (zh) * 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
US10258698B2 (en) * 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160024575A1 (en) * 2013-05-02 2016-01-28 The Regents Of The University Of California Circulating small noncoding rna markers
WO2015055857A1 (en) * 2013-10-18 2015-04-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
CA2962444C (en) * 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
WO2017136652A1 (en) * 2016-02-04 2017-08-10 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
WO2017193051A1 (en) * 2016-05-06 2017-11-09 The Trustees Of Princeton University Methods of monitoring rnase l activity
CN111448317B (zh) * 2017-12-22 2025-07-04 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
EP3749344A4 (en) * 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US12258594B2 (en) * 2018-12-05 2025-03-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof
WO2020131986A1 (en) * 2018-12-21 2020-06-25 Pioneer Hi-Bred International, Inc. Multiplex genome targeting
WO2026035744A1 (en) * 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Combination therapies for metabolic disease
WO2026035943A1 (en) * 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids

Similar Documents

Publication Publication Date Title
US12377056B2 (en) Cladribine regimen for treating multiple sclerosis
JP2025501731A5 (cg-RX-API-DMAC7.html)
US20240285668A1 (en) Formulations for oral delivery of nucleic acids
JP6430554B2 (ja) 多発性硬化症を治療するためのクラドリビン投薬計画
JP2024527340A5 (cg-RX-API-DMAC7.html)
JP2025500824A5 (cg-RX-API-DMAC7.html)
JP2025534332A (ja) 治療用核酸及びその使用方法
JP2000509715A (ja) 炎症を処置するための方法
EP0329609B1 (en) Antiviral combination
US20160324986A1 (en) Compositions and methods for providing active telomerase to cells in vivo
SK281806B6 (sk) Použitie il-10 na prípravu liečiva na prevenciu diabetes mellitus
US20240269255A1 (en) Hpv infectious disease vaccine
US7335647B2 (en) Drugs for liver diseases
JP4011618B2 (ja) 複合治療におけるtnfレセプター及びステロイドホルモン
KR20240009952A (ko) 인플루엔자 바이러스 핵산 지질 입자 백신
Chiang et al. Pharmacokinetics and antiviral activity of recombinant human interferon-βser17 in African green monkeys
Siddiqui et al. Intramuscular Interferon-β-1a: In Patients at High Risk of Developing Clinically Definite Multiple Sclerosis
WO2025188663A1 (en) Methods for the treatment of diabetes-associated autonomic neuropathy
EP4611791A1 (en) Recombinant il-12 albumin binding domain fusion proteins for use in methods for the treatment of cancer
JP2023170339A (ja) 拡張型心筋症を処置または予防するための医薬組成物
JP2003137812A (ja) 心不全の予防及び/又は治療剤
CN101500598A (zh) 治疗多发性硬化症的克拉屈滨方案
WO2006091661A1 (en) Compositions for and methods of modulating platelet levels
HK1127753B (en) Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis